Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Charles River Launches AAV and LVV Reference Materials Portfolio | Contract Pharma

What are you searching for?

Sign in
Breaking News

Charles River Launches AAV and LVV Reference Materials Portfolio

Is designed to streamline Cell and Gene Therapy research and development as it scales to Good Manufacturing Practice quality.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Charles River Laboratories International, Inc. has launched its reference materials for its adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, which is designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
 
“The launch of Charles River’s AAV and LVV reference materials portfolio is the latest in a series of enhancements in our CDMO products and services offerings,” says Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, Charles River.
 
Charles River is introducing six AAV reference material serotypes, offering superior empty and full capsid ratios and high vector genome concentration (GC/mL), plus five LVV reference material products, available with different combinations of promoters and reporter genes.
 
The additional reference materials add to the Company’s portfolio of plasmid and viral vector contract development and manufacturing organization (CDMO) offerings, reinforcing its concept-to-cure commitment to CGT researchers and developers by enabling partners to navigate the path from early discovery to commercial.
 
“This expansion of the CGT product portfolio empowers our partners to navigate the path from research to commercialization under one organization, providing a streamlined process. Combined with Charles River’s established CDMO capabilities, this enables us to continue to work towards our ultimate goal of delivering safe, effective therapies to patients faster,” adds Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics